An interventional study of Mobile antibiogram application and standard of care in Antimicrobial Prescribing Practices and Antimicrobial Resistance (AMR), sponsored by Muhimbili University of Health and Allied Sciences. Not yet recruiting at 2 sites in Tanzania. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Muhimbili University of Health and Allied Sciences · Not applicable, Interventional, and Health services research
Antimicrobial resistance (AMR) is a critical issue, especially in Africa, with resistance to common antibiotics reaching 100% in some areas. In Tanzania, limited access to culture tests and antibiograms forces healthcare providers to rely on experience for prescribing, heightening AMR risks. This study aims to determine the effectiveness of mobile antibiograms in optimizing empirical antibiotic therapy in tertiary hospitals in Tanzania.
A pragmatic quasi-experimental design (hybrid type 1 trial) will be used to evaluate the effectiveness of mobile antibiograms on antibiotic use. The key role of the antibiogram is to guide empirical treatment of symptomatic infections using antibiotics ie., the antibiogram contains a list of susceptible and resistant antibiotics enabling the prescriber to rationally choose the antibiotic which is effective in clearing the infection. The study employs a three-phase, stepwise approach to assess and enhance antimicrobial use in Tanzanian hospitals. The first phase will be a baseline assessment using World Health Organization's Point Prevalence Survey and defined daily dose (DDD) to determine the pattern of antibiotic utilization and consumption respectively. The second phase involves developing a mobile antibiogram application through a participatory design with healthcare stakeholders. The final phase will use a quasi-experimental design to test the effectiveness of the mobile antibiogram on antimicrobial stewardship metrics like DDD per 1000 patient days, antibiotic appropriateness, infection-related mortality and length of hospital stay. The study sites will be Mbeya Zonal Referral Hospital (MZRH) as the intervention group and Benjamini Mkapa Hospital (BMH) as the control group. Additionally, a mixed-methods design (explanatory sequential design) will be used to assess the acceptability, feasibility, and adoption of the mobile antibiograms.
Muhimbili University of Health and Allied Sciences is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
1. Temporarily employed prescribers
Participants will be subjected to manual antibiogram which is the standard of care to guide the empirical prescription of antibiotics
Other: standard of care
Participants will be assigned to the mobile antibiogram application to guide the empirical prescription of antibiotics in addition to standard of care.
Other: Mobile antibiogram application
A mobile antibiogram application software containing antibiotic sensitivity test results specific to the health facility. This mobile antibiogram application will guide decision support for empirical prescription.
Participants will be assigned to manual antibiogram only.
Pattern of antibiotic use
Proportional change in antibiotic use among admitted patients
Time frame: 12 months
Pattern of antibiotic resistance
Number of resistances to antibiotics among admitted patients
Time frame: 12 months
Acceptability of mobile antibiograms
% of acceptability of mobile antibiograms among prescribers
Time frame: 12 months
Feasibility of mobile antibiograms
% of feasibility mobile antibiogram among prescribers in tertiary referral hospitals in Tanzania
Time frame: 12 months
Adoption of mobile antibiogram
% of adoption of mobile antibiogram among prescribers in tertiary referral hospitals in Tanzania
Time frame: 12 months
Plan to share: No
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muhimbili University of Health and Allied Sciences